Standout Papers

Fibroblast growth factor signalling: from development to cancer 2004 2026 2011 2018 2.0k
  1. Fibroblast growth factor signalling: from development to cancer (2010)
    Nicholas C. Turner, Richard Grose Nature reviews. Cancer
  2. The history and future of targeting cyclin-dependent kinases in cancer therapy (2015)
    Uzma Asghar, Agnieszka K. Witkiewicz et al. Nature Reviews Drug Discovery
  3. Hallmarks of 'BRCAness' in sporadic cancers (2004)
    Nicholas C. Turner, Andrew Tutt et al. Nature reviews. Cancer
  4. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial (2016)
    Massimo Cristofanilli, Nicholas C. Turner et al. The Lancet Oncology
  5. Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer (2015)
    Nicholas C. Turner, Jungsil Ro et al. New England Journal of Medicine
  6. Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition (2006)
    Nuala McCabe, Nicholas C. Turner et al. Cancer Research
  7. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer (2015)
    Isaac García-Murillas, Gaia Schiavon et al. Science Translational Medicine
  8. Treating cancer with selective CDK4/6 inhibitors (2016)
    Ben O’Leary, Richard S. Finn et al. Nature Reviews Clinical Oncology
  9. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer (2018)
    Nicholas C. Turner, Dennis J. Slamon et al. New England Journal of Medicine
  10. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review (2018)
    Jason D. Merker, Geoffrey R. Oxnard et al. Journal of Clinical Oncology
  11. Advances and challenges in targeting FGFR signalling in cancer (2017)
    Irina S. Babina, Nicholas C. Turner Nature reviews. Cancer
  12. FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer (2010)
    Nicholas C. Turner, Alex Pearson et al. Cancer Research
  13. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer (2016)
    Charlotte Fribbens, Ben O’Leary et al. Journal of Clinical Oncology
  14. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer (2016)
    María Teresa Herrera-Abreu, Marta Palafox et al. Cancer Research
  15. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer (2015)
    Gaia Schiavon, Sarah Hrebien et al. Science Translational Medicine
  16. The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial (2018)
    Ben O’Leary, Rosalind Cutts et al. Cancer Discovery
  17. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group (2022)
    Javier Pascual, Gerhardt Attard et al. Annals of Oncology
  18. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial (2021)
    Eric P. Winer, Seock‐Ah Im et al. The Lancet Oncology
  19. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future (2020)
    Laura M. Spring, Seth A. Wander et al. The Lancet
  20. Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer (2019)
    Nicholas C. Turner, Yuan Liu et al. Journal of Clinical Oncology
  21. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study (2021)
    Hope S. Rugo, Florence Lerebours et al. The Lancet Oncology
  22. Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study (2022)
    Massimo Cristofanilli, Hope S. Rugo et al. Clinical Cancer Research
  23. The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment (2023)
    Sibylle Loibl, Nicholas C. Turner et al. Nature Reviews Clinical Oncology

Immediate Impact

4 by Nobel laureates 20 from Science/Nature 113 standout
Sub-graph 1 of 18

Citing Papers

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Deciphering breast cancer: from biology to the clinic
2023 Standout
19 intermediate papers

Works of Nicholas C. Turner being referenced

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
2021 Standout
FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
2010 Standout
and 31 more

Author Peers

Author Last Decade Papers Cites
Nicholas C. Turner 14460 10878 9041 11691 344 25.9k
Carlos L. Arteaga 18114 7120 6299 19578 429 34.0k
Mario Campone 14956 8736 6936 7422 532 23.2k
Matthew J. Ellis 15662 6590 12854 8868 317 26.3k
Jorma Isola 10038 5010 6205 9346 295 22.5k
P. Andrew Futreal 7666 4826 9081 16483 287 27.3k
Ana M. González-Angulo 14849 5020 11118 8771 278 24.6k
Michael F. Press 19794 4674 8487 9503 222 29.9k
John A. Foekens 11217 3560 10478 13251 337 25.1k
Edith A. Perez 20395 5671 10865 6462 395 29.5k
Sibylle Loibl 19027 8106 13044 5866 584 28.4k

All Works

Loading papers...

Rankless by CCL
2026